PL1864665T3 - Środek immunosupresyjny obejmujący związek heterocykliczny jako składnik aktywny - Google Patents

Środek immunosupresyjny obejmujący związek heterocykliczny jako składnik aktywny

Info

Publication number
PL1864665T3
PL1864665T3 PL06729002T PL06729002T PL1864665T3 PL 1864665 T3 PL1864665 T3 PL 1864665T3 PL 06729002 T PL06729002 T PL 06729002T PL 06729002 T PL06729002 T PL 06729002T PL 1864665 T3 PL1864665 T3 PL 1864665T3
Authority
PL
Poland
Prior art keywords
active ingredient
heterocyclic compound
immunosuppressive agent
immunosuppressive
agent
Prior art date
Application number
PL06729002T
Other languages
English (en)
Inventor
Kazuhiko Haruta
Shinichi Yaguchi
Toshiyuki Matsuno
Yoshio Tsuchida
Tetsuo Watanabe
Kimitomo Yoshioka
Ryogo Yui
Original Assignee
Zenyaku Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyaku Kogyo Kk filed Critical Zenyaku Kogyo Kk
Publication of PL1864665T3 publication Critical patent/PL1864665T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06729002T 2005-03-11 2006-03-13 Środek immunosupresyjny obejmujący związek heterocykliczny jako składnik aktywny PL1864665T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005069255 2005-03-11
PCT/JP2006/304937 WO2006095906A1 (ja) 2005-03-11 2006-03-13 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
EP06729002A EP1864665B1 (en) 2005-03-11 2006-03-13 Immunosuppressive agent comprising a heterocyclic compound as active ingredient

Publications (1)

Publication Number Publication Date
PL1864665T3 true PL1864665T3 (pl) 2012-10-31

Family

ID=36953490

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06729002T PL1864665T3 (pl) 2005-03-11 2006-03-13 Środek immunosupresyjny obejmujący związek heterocykliczny jako składnik aktywny

Country Status (17)

Country Link
US (2) US7750001B2 (pl)
EP (1) EP1864665B1 (pl)
JP (1) JP5089377B2 (pl)
KR (1) KR101296884B1 (pl)
CN (1) CN101137382B (pl)
AU (1) AU2006221285B2 (pl)
BR (1) BRPI0608291A2 (pl)
CA (1) CA2599879C (pl)
CY (1) CY1112886T1 (pl)
DK (1) DK1864665T3 (pl)
ES (1) ES2395196T3 (pl)
PL (1) PL1864665T3 (pl)
PT (1) PT1864665E (pl)
RU (1) RU2443441C2 (pl)
SI (1) SI1864665T1 (pl)
TW (1) TWI381841B (pl)
WO (1) WO2006095906A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128672A1 (en) * 2006-05-03 2007-11-15 Ciba Holding Inc. Substituted hexahydro-1,4-diazepin-5-ones and compositions stabilized therewith
WO2008032060A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
JP2010503648A (ja) * 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のためのｐｉ３ｋ及びｍｔｏｒ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−４−（アゼチジン、ピロリジン、ピペリジン、又はアゼピン）ピリミジン誘導体
EP2064203A1 (en) * 2006-09-14 2009-06-03 AstraZeneca AB 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090270390A1 (en) * 2006-09-14 2009-10-29 Astrazeneca Pyrimidine derivatives
WO2009066775A1 (ja) 2007-11-22 2009-05-28 Zenyaku Kogyo Kabushikikaisha 複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法
US20110053907A1 (en) * 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
KR20110120286A (ko) * 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 헤테로환 유도체
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
GB201007227D0 (en) * 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
CN103025725B (zh) * 2010-08-10 2015-09-16 安斯泰来制药有限公司 杂环化合物
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CN102429911A (zh) * 2011-12-08 2012-05-02 天津医科大学 Zstk474在制备治疗自身免性疾病药物方面的应用
RU2509770C2 (ru) * 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
WO2015047124A1 (ru) * 2013-09-26 2015-04-02 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
EP3221307B1 (en) * 2014-11-20 2019-07-24 Council of Scientific & Industrial Research Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof
CN105130960B (zh) * 2015-07-31 2018-07-06 沈阳药科大学 1,3,5-三嗪类衍生物及其应用
RU2637643C1 (ru) * 2016-09-05 2017-12-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) Иммунодепрессант
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JPWO2018131659A1 (ja) * 2017-01-11 2019-12-12 国立研究開発法人国立がん研究センター 免疫療法剤
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
EP0629622B1 (en) 1992-02-28 1998-11-11 Zenyaku Kogyo Kabushikikaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
DK0640599T3 (da) * 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-Aminopyrimidin-derivater
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0948776A (ja) 1994-09-26 1997-02-18 Dai Ichi Seiyaku Co Ltd ピリミジニルピラゾール誘導体
TW312694B (pl) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
DK1020462T3 (da) * 1997-07-24 2004-04-26 Zenyaku Kogyo Kk Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
AU3078000A (en) * 1999-01-25 2000-08-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agents containing the same as the active ingredient
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
AU2002230098B2 (en) 2001-01-30 2007-06-14 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and cognitive enhancers comprising the same as effective components
JP3836436B2 (ja) * 2001-04-27 2006-10-25 全薬工業株式会社 複素環式化合物及びそれを有効成分とする抗腫瘍剤
WO2004032930A1 (ja) 2002-10-11 2004-04-22 Kowa Co., Ltd. 癌の処置方法
DK1557415T3 (da) 2002-10-25 2012-09-17 Zenyaku Kogyo Kk Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
BR0316386A (pt) * 2002-12-06 2005-09-27 Warner Lambert Co Benzoxazin-3-onas e seus derivados como inibidores de p13k
US7855199B2 (en) * 2004-03-31 2010-12-21 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
US20070244110A1 (en) 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer

Also Published As

Publication number Publication date
WO2006095906A1 (ja) 2006-09-14
BRPI0608291A2 (pt) 2009-12-22
TW200642689A (en) 2006-12-16
US20080113987A1 (en) 2008-05-15
EP1864665A4 (en) 2008-06-11
KR20070113285A (ko) 2007-11-28
KR101296884B1 (ko) 2013-08-14
PT1864665E (pt) 2012-06-27
CN101137382B (zh) 2012-11-21
JP5089377B2 (ja) 2012-12-05
CA2599879A1 (en) 2006-09-14
HK1118016A1 (en) 2009-01-30
DK1864665T3 (da) 2012-07-23
AU2006221285B2 (en) 2011-03-31
CN101137382A (zh) 2008-03-05
JPWO2006095906A1 (ja) 2008-08-21
CA2599879C (en) 2013-07-02
RU2443441C2 (ru) 2012-02-27
ES2395196T3 (es) 2013-02-11
RU2007137651A (ru) 2009-04-20
US8338414B2 (en) 2012-12-25
US20100267700A1 (en) 2010-10-21
AU2006221285A1 (en) 2006-09-14
EP1864665A1 (en) 2007-12-12
EP1864665B1 (en) 2012-05-16
US7750001B2 (en) 2010-07-06
CY1112886T1 (el) 2016-04-13
TWI381841B (zh) 2013-01-11
SI1864665T1 (sl) 2012-09-28

Similar Documents

Publication Publication Date Title
SI1864665T1 (sl) Imunosupresivno sredstvo, ki obsega heterociklično spojino kot učinkovino
TWI369950B (en) Active compound combinations
ZA200709999B (en) Fungicidal active ingredient combination
ZA200709051B (en) Heterocyclic compound
SI1919907T1 (sl) Heterocikliäśna spojina
PL2213168T3 (pl) Pestycydowe kombinacje substancji czynnych
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
IL192298A (en) Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them
IL190895A0 (en) Pesticidal active compositions having enhanced activity
ZA200708317B (en) Herbicidally active phenylsulphonyl-urea
EP1880993A4 (en) NITROGENIC HETEROCYCLIC COMPOUND
ZA200804427B (en) Nanoparticulate active ingredient formulations
IL186359A0 (en) Synergistic fungicidal active substance combinations
PL2154968T3 (pl) Kombinacje grzybobójczych substancji czynnych
IL187916A0 (en) Tablet containing hardly soluble active ingredient
ZA200804757B (en) Fungicidal active ingredient combination
GB0402492D0 (en) Pharmaceutically active compounds
ZA200804952B (en) Fungicidal active substance combination
ZA200805137B (en) Fungicidal active compound combination
EP1776112A4 (en) HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
ZA200900207B (en) Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
IL190277A0 (en) Aril-substituted nitrogen-containing heterocyclic compound
EP1884237A4 (en) NEUROCYTE PROTECTIVE AGENT COMPRISING AN AMIDINO DERIVATIVE AS AN ACTIVE SUBSTANCE
ZA200800142B (en) Heterocyclic compound
EP1884236A4 (en) ANGIOGENESIS INHIBITOR CONTAINING AN AMINATED DERIVATIVE AS AN ACTIVE SUBSTANCE